In the benefit assessment of drugs, it may happen that a benefit must be re-examined in a subpopulation, for example if the approval is restricted to a subpopulation which particularly benefits from the treatment. In these ...
NICE are currently undergoing what appears to be quite a wide re-evaluation of their HTA process. As part of this process, they have recently released a white paper for comment, entitled “The NICE methods of health technology ...
By clicking "Accept," you agree to the use of Numerus and third party cookies and other similar technologies to enhance your browsing experience, analyse, and measure your engagement with our content.
